TONMYA is now available by prescription and available for pharmacy ordering nationwideTONMYA is the first FDA-approved treatment for fibromyalgia ...
Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as ...
NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”) , a multi–Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers today ...
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat ...
Primary central nervous system lymphoma (PCNSL) is a rare and highly aggressive lymphoma or tumor of the brain. While ...
These subgroup insights will guide trial design, patient selection, and endpoint strategy for Autonomix's upcoming U.S.-based multicenter clinical study, currently planned to begin in 2026, which will ...
TONMYA was approved by the FDA on August 15, 2025.
Indian pharmaceutical market records healthy 5-year CAGR of over 10 per cent: Our Bureau, Chennai Saturday, November 8, 2025, 08:00 Hrs [IST] The Indian Pharmaceutical Market (IPM ...
Join me for a 30-minute Yin Yoga session that will help you stretch out your tight hips, hamstrings, and full body. This is the perfect practice for all levels and will leave you feeling relaxed and ...
Kyverna Therapeutics (KYTX) is rated a strong buy with promising KYV-101 Phase 2 data and near-term catalysts. Read here for ...
Australian researchers have identified two nervous system components that drive tumor growth in gastrointestinal cancers, creating promising new avenues for treatment with existing approved therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback